Phase I Trial of Prednisone, Abiraterone, Cabazitaxel and Enzalutamide (PACE) for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2018
Price : $35 *
At a glance
- Drugs Abiraterone (Primary) ; Cabazitaxel (Primary) ; Enzalutamide (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 31 Jul 2018 Planned End Date changed from 1 Mar 2023 to 1 Aug 2023.
- 31 Jul 2018 Planned primary completion date changed from 1 Mar 2021 to 1 Aug 2021.